CREATIVE MEDICAL TECHNOLOGY CELZ
ASignal's systematic analysis rates CELZ as Bearish.
Reflects the latest available analysis · analyzed Nov 18, 2026
The case on CELZ
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (66.87%) indicating pricing power or low production costs
- High cash position relative to debt (debt-to-equity: 0.00x)
- Strong liquidity with current ratio of 23.66x and quick ratio of 23.35x
- RSI at 23.57 suggesting potential oversold condition
- Negative MACD and declining momentum (MACD histogram negative and price momentum -0.23)
- Price significantly below key moving averages (SMA20, SMA50)
- Massive negative operating margin (-256,435%) indicating severe operational losses
- Negative return on equity (-118.72%) and return on assets (-73.23%)
- Extremely high price-to-sales ratio (1180.91x) and negative enterprise value (-$3.18M)
- No news coverage or Reddit mentions, indicating lack of market interest or information
See the full verdict on CELZ
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CELZ
Most investors never get a second opinion, let alone several. ASignal runs CELZ past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.